Literature DB >> 10536006

The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.

B Lutterbach1, Y Hou, K L Durst, S W Hiebert.   

Abstract

The inv(16) is one of the most frequent chromosomal translocations associated with acute myeloid leukemia (AML). The inv(16) fusion protein acts by dominantly interfering with AML-1/core binding factor beta-dependent transcriptional regulation. Here we demonstrate that the inv(16) fusion protein cooperates with AML-1B to repress transcription. This cooperativity requires the ability of the translocation fusion protein to bind to AML-1B. Mutational analysis and cell fractionation experiments indicated that the inv(16) fusion protein acts in the nucleus and that repression occurs when the complex is bound to DNA. We also found that the inv(16) fusion protein binds to AML-1B when it is associated with the mSin3A corepressor. An AML-1B mutant that fails to bind mSin3A was impaired in cooperative repression, suggesting that the inv(16) fusion protein acts through mSin3 and possibly other corepressors. Finally, we demonstrate that the C-terminal portion of the inv(16) fusion protein contains a repression domain, suggesting a molecular mechanism for AML-1-mediated repression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536006      PMCID: PMC23113          DOI: 10.1073/pnas.96.22.12822

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.

Authors:  S W Hiebert; W Sun; J N Davis; T Golub; S Shurtleff; A Buijs; J R Downing; G Grosveld; M F Roussell; D G Gilliland; N Lenny; S Meyers
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit.

Authors:  T Kanno; Y Kanno; L F Chen; E Ogawa; W Y Kim; Y Ito
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

3.  Groucho-dependent and -independent repression activities of Runt domain proteins.

Authors:  B D Aronson; A L Fisher; K Blechman; M Caudy; J P Gergen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells.

Authors:  W Cao; M Britos-Bray; D F Claxton; C A Kelley; N A Speck; P P Liu; A D Friedman
Journal:  Oncogene       Date:  1997-09       Impact factor: 9.867

5.  The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo.

Authors:  Q Wang; T Stacy; J D Miller; A F Lewis; T L Gu; X Huang; J H Bushweller; J C Bories; F W Alt; G Ryan; P P Liu; A Wynshaw-Boris; M Binder; M Marín-Padilla; A H Sharpe; N A Speck
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

6.  Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-alpha transcription factors.

Authors:  C Zeng; A J van Wijnen; J L Stein; S Meyers; W Sun; L Shopland; J B Lawrence; S Penman; J B Lian; G S Stein; S W Hiebert
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.

Authors:  D A Yergeau; C J Hetherington; Q Wang; P Zhang; A H Sharpe; M Binder; M Marín-Padilla; D G Tenen; N A Speck; D E Zhang
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

8.  Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor.

Authors:  M Niki; H Okada; H Takano; J Kuno; K Tani; H Hibino; S Asano; Y Ito; M Satake; T Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 9.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

10.  Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.

Authors:  P P Liu; C Wijmenga; A Hajra; T B Blake; C A Kelley; R S Adelstein; A Bagg; J Rector; J Cotelingam; C L Willman; F S Collins
Journal:  Genes Chromosomes Cancer       Date:  1996-06       Impact factor: 5.006

View more
  33 in total

1.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

Review 2.  Leukaemogenesis: more than mutant genes.

Authors:  Jianjun Chen; Olatoyosi Odenike; Janet D Rowley
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

4.  CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis.

Authors:  G Cordonnier; A Mandoli; A Radhouane; G Hypolite; L Lhermitte; M Belhocine; V Asnafi; E Macintyre; J H A Martens; S Fumagalli; J Bond
Journal:  Leukemia       Date:  2017-02-15       Impact factor: 11.528

5.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 6.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

7.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

8.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.

Authors:  R Katherine Hyde; Yasuhiko Kamikubo; Stacie Anderson; Martha Kirby; Lemlem Alemu; Ling Zhao; P Paul Liu
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

9.  Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Authors:  Olatoyosi M Odenike; Serhan Alkan; Dorie Sher; John E Godwin; Dezheng Huo; Stephen J Brandt; Margaret Green; Jingping Xie; Yanming Zhang; David H Vesole; Patrick Stiff; John Wright; Richard A Larson; Wendy Stock
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  The C-terminus of CBFβ-SMMHC is required to induce embryonic hematopoietic defects and leukemogenesis.

Authors:  Yasuhiko Kamikubo; R Katherine Hyde; Ling Zhao; Lemlem Alemu; Cecilia Rivas; Lisa J Garrett; P Paul Liu
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.